Matinas BioPharma (MTNB) Misses Q1 EPS by 1c
Matinas BioPharma (NYSE: MTNB) reported Q1 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)